Catalyst Pharmaceuticals Reports Record 2025 Results, Strong 2026 Guidance, and Major FIRDAPSE Royalty Reduction

summarizeSummary

Catalyst Pharmaceuticals reported record 2025 financial results, provided strong 2026 revenue guidance, and announced a significant reduction in FIRDAPSE royalty rates, alongside an ongoing share repurchase program.

check_boxKey Events

• Record 2025 Financial Performance

  The company reported record full-year 2025 total revenues of $589.0 million, representing 19.8% year-over-year growth, and GAAP net income of $214.3 million, up 30.8% year-over-year. Cash and cash equivalents increased 37% to $709.2 million.

• Strong 2026 Revenue Guidance

  Catalyst Pharmaceuticals provided full-year 2026 total revenue guidance of $615 million to $645 million, reflecting continued robust growth for FIRDAPSE and AGAMREE, with promoted product revenue expected to grow by 20% or more.

• Significant FIRDAPSE Royalty Reduction

  Effective January 26, 2026, the overall royalty rate paid to upstream licensors for net U.S. sales of FIRDAPSE will decrease to 6% from a previous maximum rate of 18.5%, which is expected to substantially improve future profitability.

• Ongoing Share Repurchase Program

  The company announced a $200 million share repurchase program in Q4 2025 and has already repurchased 1,740,713 shares for approximately $39.9 million at an average price of $22.91 per share, demonstrating confidence in its long-term outlook.

auto_awesomeAnalysis

Catalyst Pharmaceuticals delivered record financial performance in 2025, driven by robust growth in its key products, FIRDAPSE and AGAMREE. The company's 2026 revenue guidance is strong, projecting continued expansion. A highly significant development is the substantial reduction in FIRDAPSE royalty rates, which is expected to materially enhance future gross margins and profitability. Furthermore, the ongoing share repurchase program underscores management's confidence in the company's valuation and commitment to shareholder returns. This comprehensive update paints a very positive picture for the company's operational and financial trajectory.